Pegapamodutide is under clinical development by OPKO Health and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pegapamodutide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pegapamodutide overview

Pegapamodutide (LY-2944876) is under development for the treatment of type 2 diabetes and obesity. It is administered once or twice weekly through subcutaneous route. LY-2944876 is an Oxyntomodulin peptide that acts on glucagon-like peptides-1 (GLP-1) receptor and glucagon receptor.

OPKO Health overview

OPKO Health (OPKO) discovers, develops, manufactures, and commercializes novel diagnostic technologies and pharmaceuticals products. The company’s product portfolio includes 4K score test used for diagnosis of prostate cancer; Rayaldee (calcifediol), an extended-release capsule for treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease; and the Claros analyzer, a blood performance test. OPKO develops products using proprietary technologies including, Carboxyl Terminal Peptide (CTP) technology, Reversible PEGylation and AntagoNAT technology. It is advancing pipeline products targeted for the treatment of hypophosphatemia, obesity, diabetes, haemophilia, growth hormone deficiency, dravet syndrome and other diseases. It also offers veterinary products. The company has operational presence with offices located in Chile, Mexico, Spain, Ireland, Canada, and Israel. OPKO is headquartered in Miami, Florida, the US.

For a complete picture of Pegapamodutide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.